Jones Hill Capital LP
CIK 2102314 · View on SEC EDGAR ↗
- Portfolio value
- $470.4M
- Positions
- 29
- As of
- June 30, 2026
#3,930 of 9,443 by 13F value · top 41.6%
Portfolio value QoQ: +0.8% 13F does not disclose cash
- Top 10 holdings weight
- 68.84%
- Top 25 holdings weight
- 98.59%
- Positions above 1%
- 25
- Effective number of positions
- 14.7
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 58.88% Est. buys $275,809,337 · sells $311,555,215
- New positions
- 15
- Increased
- 5
- Decreased
- 9
- Closed
- 12
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 94.1% · Options excluded: 0.0%
Sector breakdown
Healthcare
98.2%
Other/Unmapped
1.8%
Full portfolio 29 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| BMRN BioMarin Pharmaceutical Inc. - Common Stock | $81,915,580 | 17.42% | 1,431,590 | $10,264,229 | Up ×1 | ||
| GILD Gilead Sciences, Inc. - Common Stock | $43,340,053 | 9.21% | 343,043 | Up ×1 | |||
| ARQT Arcutis Biotherapeutics, Inc. - Common stock | $28,571,960 | 6.07% | 1,089,701 | Up ×1 | |||
| MDGL Madrigal Pharmaceuticals, Inc. - Common Stock | $28,214,038 | 6.00% | 52,545 | Up ×1 | |||
| BCAX Bicara Therapeutics Inc. - Common Stock | $26,501,917 | 5.63% | 892,621 | $1,437,812 | Down ×1 | ||
| RLMD Relmada Therapeutics, Inc. - Common Stock | $25,293,119 | 5.38% | 3,655,075 | $22,907,565 | Up ×1 | ||
| TRVI Trevi Therapeutics, Inc. - Common Stock | $24,976,304 | 5.31% | 1,339,212 | $20,560,116 | Up ×1 | ||
| PHVS Pharvaris N.V. - Ordinary Shares | $23,441,056 | 4.98% | 677,879 | $18,722,910 | Up ×1 | ||
| XENE Xenon Pharmaceuticals Inc. - Common Shares | $22,206,444 | 4.72% | 367,900 | Up ×1 | |||
| ANIP ANI Pharmaceuticals, Inc. - Common Stock | $19,354,626 | 4.11% | 233,808 | $-5,145,022 | Down ×1 | ||
| IMCR Immunocore Holdings plc - American Depositary Shares | $16,283,178 | 3.46% | 512,856 | Up ×1 | |||
| AMLX Amylyx Pharmaceuticals, Inc. - Common Stock | $16,057,282 | 3.41% | 894,058 | $-6,165,955 | Down ×1 | ||
| INSM Insmed Incorporated - Common Stock | $13,047,622 | 2.77% | 122,375 | Up ×1 | |||
| NUVL Nuvalent, Inc. - Class A Common Stock | $12,157,587 | 2.58% | 98,442 | $-18,662,447 | Down ×1 | ||
| CAPR Capricor Therapeutics, Inc. - Common Stock | $10,131,684 | 2.15% | 420,751 | $-17,508,209 | Down ×1 | ||
| ACRS Aclaris Therapeutics, Inc. - Common Stock | $9,307,713 | 1.98% | 1,759,492 | Up ×1 | |||
| Unknown issuer (CUSIP: 4525EP200) | $8,296,941 | 1.76% | 539,814 | Up ×1 | |||
| ORIC Oric Pharmaceuticals, Inc. - Common Stock | $8,093,400 | 1.72% | 747,313 | Up ×1 | |||
| TNXP Tonix Pharmaceuticals Holding Corp. - Common Stock | $7,980,461 | 1.70% | 625,428 | $1,763,866 | Up ×1 | ||
| SNDX Syndax Pharmaceuticals, Inc. - Common Stock | $7,432,400 | 1.58% | 340,000 | Up ×1 | |||
| OLMA Olema Pharmaceuticals, Inc. - Common Stock | $7,182,817 | 1.53% | 574,166 | Up ×1 | |||
| VIR Vir Biotechnology, Inc. - Common Stock | $6,717,380 | 1.43% | 659,213 | $-4,018,608 | Down ×1 | ||
| CRBP Corbus Pharmaceuticals Holdings, Inc. - Common Stock | $6,130,505 | 1.30% | 653,572 | Up ×1 | |||
| DNTH Dianthus Therapeutics, Inc. - Common Stock | $5,566,108 | 1.18% | 57,100 | Up ×1 | |||
| VRTX Vertex Pharmaceuticals Incorporated - Common Stock | $5,525,128 | 1.17% | 11,123 | $-42,970,456 | Down ×1 | ||
| ELVN Enliven Therapeutics, Inc. - Common Stock | $2,529,888 | 0.54% | 49,850 | $-20,717,280 | Down ×1 | ||
| GPCR Structure Therapeutics Inc. - American Depositary Shares | $2,177,231 | 0.46% | 40,567 | $-2,671,352 | Down ×1 | ||
| PHAT Phathom Pharmaceuticals, Inc. - Common Stock | $1,752,123 | 0.37% | 161,486 | Up ×1 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $174,743 | 0.04% | 26,760 | Up ×1 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| GILD | $43,340,053 | 343,043 | 9.21% |
| ARQT | $28,571,960 | 1,089,701 | 6.07% |
| MDGL | $28,214,038 | 52,545 | 6.00% |
| XENE | $22,206,444 | 367,900 | 4.72% |
| IMCR | $16,283,178 | 512,856 | 3.46% |
| INSM | $13,047,622 | 122,375 | 2.77% |
| ACRS | $9,307,713 | 1,759,492 | 1.98% |
| Unknown issuer (CUSIP: 4525EP200) | $8,296,941 | 539,814 | 1.76% |
| ORIC | $8,093,400 | 747,313 | 1.72% |
| SNDX | $7,432,400 | 340,000 | 1.58% |
| OLMA | $7,182,817 | 574,166 | 1.53% |
| CRBP | $6,130,505 | 653,572 | 1.30% |
| DNTH | $5,566,108 | 57,100 | 1.18% |
| PHAT | $1,752,123 | 161,486 | 0.37% |
| ACHV | $174,743 | 26,760 | 0.04% |
Top movers (QoQ)
| Security | Action | Shares Δ | Value Δ |
|---|---|---|---|
| PHVS | Bought more | +511K | +$18.7M |
| NUVL | Trimmed | -202K | -$18.7M |
| CAPR | Trimmed | -488K | -$17.5M |
| BMRN | Bought more | +163K | +$10.3M |
| AMLX | Trimmed | -705K | -$6.2M |
| ANIP | Trimmed | -85K | -$5.1M |
| VIR | Trimmed | -539K | -$4.0M |
| GPCR | Trimmed | -60K | -$2.7M |
| TNXP | Bought more | +173K | +$1.8M |
| BCAX | Trimmed | -368K | +$1.4M |
4 positions hidden (data completeness check)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| PCVX | June 30, 2026 | 644,831 | $37,471,129 | 7.2% |
| TERN | June 30, 2026 | 521,237 | $27,479,615 | No longer tracked |
| RARE | June 30, 2026 | 1,165,557 | $24,418,419 | -21.8% |
| ARGX | June 30, 2026 | 25,995 | $18,982,849 | 11.7% |
| FULC | June 30, 2026 | 1,771,926 | $13,590,672 | 6.0% |
| NUVB | June 30, 2026 | 2,383,031 | $10,223,203 | 23.0% |
| ORKA | June 30, 2026 | 140,843 | $6,908,349 | 12.4% |
| CTNM | June 30, 2026 | 513,053 | $6,700,472 | -2.4% |
| MANE | June 30, 2026 | 100,843 | $6,368,235 | -14.8% |
| TRDA | June 30, 2026 | 374,010 | $4,720,006 | 4.2% |
| SLN | June 30, 2026 | 301,604 | $1,589,453 | 20.8% |
| AVBP | June 30, 2026 | 45,809 | $1,056,814 | -15.5% |